Literature DB >> 22754785

Innate predisposition to immune escape in follicular lymphoma cells.

Pauline Gravelle1, Christine Jean, Wilfried Valleron, Guy Laurent, Jean-Jacques Fournié.   

Abstract

Tumor-intrinsic immuno-resistance is a prerequisite for emergence of follicular lymphomas. Here we show that in vitro, such cells are more resistant to immune cytolysis when grown as follicle-mimicking tridimensional aggregates than when grown as cell suspensions. So in patients, this innate adaptation to tumor immunity might precede its selective pressure.

Entities:  

Year:  2012        PMID: 22754785      PMCID: PMC3382883          DOI: 10.4161/onci.19365

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


The cure of non-Hodgkin lymphomas (NHL) largely depends upon cytolytic lymphocytes recruited during therapy, but most NHL cells appear relatively resistant to their action. It is thus important to understand how they do so. A hallmark of follicular lymphoma is their growth as dense aggregates in lymph nodes, a feature however lacking from all in vitro studies which currently involve cell suspensions only. Here we grew lymphoma cells in vitro as tridimensional multicellular aggregates (MALC) to test whether such a mode of cell growth promotes some degree of immuno-resistance. In this aim, MALC of the t(14,18)+ follicular lymphoma cell line RL were produced in vitro by a modified “hanging drop” method., This type of cell growth formed compact ovoïd aggregates reaching a diameter of ~1 mm by three weeks of culture, which were never produced in the usual cell suspensions in culture flasks. We then asked whether these two kinds of cell growth induced different gene expression profiles. So, the transcriptomes from RL cells grown for 10 d either as MALC or cell suspensions were produced on Affymetrix microarrays (HG-133 plus 2.0) and analyzed by Autocompare. 451 genes were significantly upregulated in cells grown as MALC comparatively to cell suspensions (> 4×, p < 0.05). These were enriched for genes upregulated in the central area of tumors relative to periphery (p = 10−20) and for genes regulated by the histone-lysine N-methyltransferase gene EZH2 (p = 10−12). The upregulated MALC genes also reflected the highly relevant hallmarks of follicular lymphoma cells: induction of anti-apoptotic functions (p = 0.0002), pro-survival NFκB cascade (p = 0.0006) and response to hypoxia (p = 0.002). Further, the 241 most downregulated MALC genes (< 0.5×, p < 0.05) indicated shut down of cytokine/cytokine receptor interactions (p = 10−7) and chemokine signaling (p = 10−5). So, lymphoma cells grown in vitro as MALC present a gene expression pattern which is not only highly relevant of follicular lymphoma cells in vivo, but also suggests a pre-adaptation to selective pressure from immunity. This view was strenghened when the lymphoma cells grown either in culture flasks or MALC were dissociated and compared as targets in classical 4 h 51Cr-release lysis assays by allogeneic NK cells from different healthy donors. The lymphoma cells were more resistant to NK lysis when grown as MALC than when grown as cell suspensions (Fig. 1).

Figure 1. Follicular lymphoma cell growth in vitro as MALC increases immune resistance.

Figure 1. Follicular lymphoma cell growth in vitro as MALC increases immune resistance. Various lymphoma cell-intrinsic immuno-escape pathways such as altered HLA-I, CD58, IDO and deficient immune synapses have been identified. We now propose that growth as cell aggregates represent another tumor cell-intrinsic pathway of immuno-resistance for follicular lymphomas. The transcriptome of follicular lymphoma cells grown as MALC was characteristic of deeply intra-tumoral cancer cells and reflected regulation by known drivers of lymphomagenesis. Together with these features, cells from MALC showed more anti-apoptotic and “immunosilent” gene expression profiles and they showed higher resistance to NK lysis than cells in suspension. So when grown aggregated in vitro, the lymphoma cells show a remarkable tumor-intrinsic pre-adaptation to further immune pressure. These observations suggest that natural lymphomagenesis in lymphoid organs from patients might also involve such an “innate” predisposition to immune escape.
  9 in total

1.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

Authors:  Madhavi Challa-Malladi; Yen K Lieu; Olivia Califano; Antony B Holmes; Govind Bhagat; Vundavalli V Murty; David Dominguez-Sola; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

2.  The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures.

Authors:  Fréderic Pont; Julien Familiades; Sébastien Déjean; Séverine Fruchon; Delphine Cendron; Mary Poupot; Rémy Poupot; Fatima L'faqihi-Olive; Nais Prade; Bernard Ycart; Jean-Jacques Fournié
Journal:  Eur J Immunol       Date:  2011-12-02       Impact factor: 5.532

Review 3.  Aggressive lymphomas.

Authors:  Georg Lenz; Louis M Staudt
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemura; Naoe Goto; Senji Kasahara; Masahito Shimizu; Hiroyasu Ito; Kuniaki Saito; Yoshinobu Hirose; Tetsuya Yamada; Takeshi Takahashi; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Ann Hematol       Date:  2010-10-12       Impact factor: 3.673

5.  In vivo model of follicular lymphoma resistant to rituximab.

Authors:  Stéphane Dalle; Sophie Dupire; Stéphanie Brunet-Manquat; Lina Reslan; Adriana Plesa; Charles Dumontet
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

6.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

7.  The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.

Authors:  M Nuytten; L Beke; A Van Eynde; H Ceulemans; M Beullens; P Van Hummelen; F Fuks; M Bollen
Journal:  Oncogene       Date:  2007-09-03       Impact factor: 9.867

8.  Zonal heterogeneity for gene expression in human pancreatic carcinoma.

Authors:  Toru Nakamura; Toshio Kuwai; Yasuhiko Kitadai; Takamitsu Sasaki; Dominic Fan; Kevin R Coombes; Sun-Jin Kim; Isaiah J Fidler
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

9.  Generation of multicellular tumor spheroids by the hanging-drop method.

Authors:  Nicholas E Timmins; Lars K Nielsen
Journal:  Methods Mol Med       Date:  2007
  9 in total
  6 in total

1.  Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Authors:  Cédric Rossi; Pauline Gravelle; Emilie Decaup; Julie Bordenave; Mary Poupot; Marie Tosolini; Don-Marc Franchini; Camille Laurent; Renaud Morin; Jean-Michel Lagarde; Loïc Ysebaert; Laetitia Ligat; Christine Jean; Ariel Savina; Christian Klein; Alba Matas Céspedes; Patricia Perez-Galan; Jean-Jacques Fournié; Christine Bezombes
Journal:  Oncoimmunology       Date:  2018-12-17       Impact factor: 8.110

Review 2.  Three-dimensional models: a novel approach for lymphoma research.

Authors:  Maura Rossi; Francesco Alviano; Simona Righi; Elena Sabattini; Claudio Agostinelli
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-29       Impact factor: 4.553

Review 3.  Trial Watch: Proteasomal inhibitors for anticancer therapy.

Authors:  Florine Obrist; Gwenola Manic; Guido Kroemer; Ilio Vitale; Lorenzo Galluzzi
Journal:  Mol Cell Oncol       Date:  2014-12-01

4.  A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.

Authors:  Emilie Decaup; Cédric Rossi; Pauline Gravelle; Camille Laurent; Julie Bordenave; Marie Tosolini; Anne Tourette; Emeline Perrial; Charles Dumontet; Mary Poupot; Christian Klein; Ariel Savina; Jean-Jacques Fournié; Christine Bezombes
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

5.  Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.

Authors:  E Decaup; C Jean; C Laurent; P Gravelle; S Fruchon; F Capilla; A Marrot; T Al Saati; F-X Frenois; G Laurent; C Klein; N Varoqueaux; A Savina; J-J Fournié; C Bezombes
Journal:  Blood Cancer J       Date:  2013-08-09       Impact factor: 11.037

6.  3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma.

Authors:  Fabien Gava; Carla Faria; Pauline Gravelle; Juan G Valero; Cèlia Dobaño-López; Renaud Morin; Marine Norlund; Aurélie Gomes; Jean-Michel Lagarde; Cédric Rossi; Julie Bordenave; Laetitia Pieruccioni; Jacques Rouquette; Alba Matas-Céspedes; Jean-Jacques Fournié; Loïc Ysebaert; Camille Laurent; Patricia Pérez-Galán; Christine Bezombes
Journal:  Cancers (Basel)       Date:  2021-03-24       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.